Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 1
2012 2
2017 1
2019 3
2020 2
2022 2
2023 1
2024 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Mok TSK, et al. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955977 Clinical Trial.
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.
He J, Tsuboi M, Weder W, Chen KN, Hochmair MJ, Shih JY, Lee SY, Lee KY, Nhung NV, Saeteng S, Liu L, Xing L, Gia NH, Murakami S, Han Y, Saavedra MP, Yoon SH, Teixeira CHA, Escriu C, Martinez-Marti A, Blakely CM, Yatabe Y, Dacic S, Rukazenkov Y, Huang X, Dayal A, Chaft JE; NeoADAURA Investigators. He J, et al. J Clin Oncol. 2025 Sep 10;43(26):2875-2887. doi: 10.1200/JCO-25-00883. Epub 2025 Jun 2. J Clin Oncol. 2025. PMID: 40454705 Clinical Trial.
Immunotherapy and Biomarkers in Sarcoma.
Dajsakdipon T, Siripoon T, Ngamphaiboon N, Ativitavas T, Dejthevaporn T. Dajsakdipon T, et al. Among authors: ativitavas t. Curr Treat Options Oncol. 2022 Mar;23(3):415-438. doi: 10.1007/s11864-022-00944-6. Epub 2022 Mar 9. Curr Treat Options Oncol. 2022. PMID: 35262852 Review.
Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer.
Nag S, Ray Coquard I, Gupta S, Pathak A, Li N, Mulya Sari R, Harano K, Kim GM, Ang SF, Que FV, Chay WY, Lai HC, Ativitavas T, Tangjitgamol S, Lai CH, Heong VYM, Contreras Tolentino J, Ngu MR, Yun J, Yunokawa M, Hanafi WLH, Li J, Smyth E, Yoshino T, Mehta J, Pentheroudakis G, Maheshwari A, Cervantes A, Basade M, Oaknin A. Nag S, et al. Among authors: ativitavas t. ESMO Open. 2025 Jun;10(6):105125. doi: 10.1016/j.esmoop.2025.105125. Epub 2025 Jun 9. ESMO Open. 2025. PMID: 40494042 Free PMC article.
Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer.
Saifon W, Sensorn I, Trachu N, Oranratnachai S, Charoenyingwattana A, Runcharoen C, Monnamo N, Sukkasem W, Inchareon P, Suwatanapongched T, Chansriwong P, Ativitavas T, Panvichian R, Chantratita W, Reungwetwattana T. Saifon W, et al. Among authors: ativitavas t. BMC Cancer. 2022 Sep 8;22(1):963. doi: 10.1186/s12885-022-10050-3. BMC Cancer. 2022. PMID: 36076157 Free PMC article.
Molecular alterations and clinical prognostic factors in resectable non-small cell lung cancer.
Thamrongjirapat T, Muntham D, Incharoen P, Trachu N, Sae-Lim P, Sarachai N, Khiewngam K, Monnamo N, Kantathut N, Ngodngamthaweesuk M, Ativitavas T, Chansriwong P, Nitiwarangkul C, Ruangkanchanasetr R, Kositwattanarerk A, Sirachainan E, Dejthevaporn T, Reungwetwattana T. Thamrongjirapat T, et al. Among authors: ativitavas t. BMC Cancer. 2024 Feb 13;24(1):200. doi: 10.1186/s12885-024-11934-2. BMC Cancer. 2024. PMID: 38347487 Free PMC article.
15 results